Hims vs Sequence 2026: GLP-1 Weight Loss Programs Compared

Head-to-Head Comparison Table

The following table compares Hims, Sequence, and Trimi across the factors that matter most for patients choosing a GLP-1 weight loss provider. All pricing reflects data observed in early 2026.

Pricing Analysis: Budget Platform vs Premium Program

The pricing gap between Hims and Sequence is the widest among commonly compared GLP-1 provider pairs, and it reflects genuinely different business models rather than just different margins on the same service. GLP-1 therapy is not a one-month experiment — most patients need 6 to 12 months of continuous treatment to reach meaningful weight loss goals, and many continue maintenance dosing indefinitely. Monthly cost differences compound into thousands of dollars over a typical treatment course, making pricing analysis essential before committing.

Hims prices compounded semaglutide between approximately $149 and $199 per month depending on dose tier. Tirzepatide pricing ranges from $199 to $299 per month. Consultations are bundled into the plan cost, and Hims does not charge a separate evaluation fee. This bundled approach simplifies cost calculations and positions Hims as one of the more affordable options among widely recognized GLP-1 telehealth platforms. However, Hims is not the cheapest option on the market — it is the cheapest among the large brand-name platforms.

Sequence prices compounded semaglutide between approximately $249 and $399 per month, with tirzepatide ranging from $349 to $399 per month. Sequence justifies this premium through access to board-certified obesity medicine specialists, comprehensive metabolic assessments, video consultations, and more intensive clinical oversight throughout treatment. For patients with complex metabolic profiles or comorbidities that benefit from specialist management, this premium may deliver clinical value that lower-cost platforms cannot match. For patients with straightforward obesity treatment needs, the premium may be difficult to justify when the same active medication is available elsewhere.

At Trimi, compounded semaglutide costs $99 per month and compounded tirzepatide costs $125 per month. There is no consultation fee, no enrollment fee, and no contract. A patient taking semaglutide for 12 months at Trimi pays $1,188 total. The same patient at Hims pays $1,788 to $2,388. At Sequence, that figure climbs to $2,988 to $4,788 — meaning the annual difference between Trimi and Sequence can exceed $3,600. For patients weighing the cheapest GLP-1 options in 2026, this gap is significant enough to influence provider choice for many households.

Medications and Access: What Each Platform Prescribes

Both Hims and Sequence prescribe compounded versions of the two most clinically validated GLP-1 weight loss medications: semaglutide and tirzepatide. The active pharmaceutical ingredients are identical to those in the brand-name products Wegovy, Ozempic, Zepbound, and Mounjaro. Compounded medications are prepared by accredited pharmacies under FDA-regulated conditions, and the pharmacological effect is the same regardless of which telehealth platform facilitates the prescription.

Hims offers both compounded semaglutide and compounded tirzepatide, distributing medications through an established network of compounding pharmacy partners built over years of large-scale telehealth operations across multiple health categories. Patients manage prescriptions, refills, and dose adjustments through the Hims app. Tirzepatide availability has varied depending on regulatory conditions and pharmacy capacity, though both medications are generally available through the platform.

Sequence offers compounded GLP-1 medications and has historically also facilitated access to branded GLP-1 medications — Wegovy, Zepbound, and others — for patients with insurance coverage that extends to these products. This dual access model is one of Sequence's distinctive features: patients whose insurance covers branded GLP-1 medications can potentially access them through Sequence's network, while those paying cash can use compounded versions. Sequence's obesity medicine specialists may also prescribe complementary medications or combination approaches based on individual metabolic assessments, drawing on their specialized training to customize treatment beyond standard GLP-1 monotherapy.

Trimi offers both compounded semaglutide and compounded tirzepatide as core offerings with consistent availability. Because Trimi focuses specifically on metabolic health and GLP-1 therapy, medication supply continuity is a central operational priority rather than one product line among many. Patients who start with semaglutide and later want to transition to tirzepatide — or vice versa based on clinical response and tolerability — can do so seamlessly within the same platform and provider relationship. For patients interested in understanding the differences between these medications, our semaglutide and tirzepatide treatment pages detail mechanisms, dosing protocols, and expected outcomes.

Provider Experience: Generalist vs Obesity Specialist

The provider experience is where Hims and Sequence diverge most dramatically, and it represents the core trade-off patients must evaluate when choosing between these platforms. GLP-1 therapy involves dose titration decisions, side effect management, treatment duration planning, and ongoing clinical monitoring — all of which benefit from provider expertise and engagement. The question is how much that expertise is worth and whether the premium Sequence charges translates into measurably better outcomes for your specific clinical situation.

Hims operates primarily through an app-based asynchronous model. Patients complete an online health questionnaire, a provider reviews the submission, and if appropriate, a prescription is issued without a live consultation. This approach is fast and convenient — many patients receive prescriptions within 24 to 48 hours. The trade-off is limited clinical dialogue. When you have questions about managing Hims weight loss side effects like nausea, constipation, or injection site reactions, the asynchronous model can feel impersonal. Hims providers cover dozens of health categories, meaning the provider reviewing your weight loss case has likely also handled hair loss, skincare, and mental health consultations the same day.

Sequence's provider model is built around board-certified obesity medicine physicians — clinicians who have completed additional fellowship training and certification specifically in treating obesity and related metabolic conditions through the American Board of Obesity Medicine (ABOM). These specialists understand GLP-1 pharmacology at a deeper level than general practitioners, including optimal dose titration schedules, drug interaction profiles, metabolic comorbidity management, and when to consider switching medications or adding complementary therapies. For patients with Sequence-specific side effect concerns, having a specialist provider can mean more nuanced clinical guidance. Sequence consultations typically include video visits and ongoing provider engagement, creating a more interactive clinical relationship.

Trimi's provider model occupies a middle ground that many patients find optimal. Trimi providers focus exclusively on weight management and metabolic health, developing deep expertise in GLP-1 therapy through daily clinical practice in this specific area. This specialization delivers meaningfully better care than generalist telehealth models without requiring the formal ABOM certification that drives Sequence's premium pricing. Trimi's web and messaging-based system allows patients to communicate directly with their care team for dose questions, side effect guidance, and treatment adjustments without additional fees.

Clinical Evidence: Results Come from the Medication, Not the Brand

A critical point that sometimes gets obscured in provider comparisons: your weight loss outcomes are determined primarily by the medication, the dose, and your adherence to treatment — not which telehealth platform delivered the prescription. The clinical evidence supporting GLP-1 medications for weight loss is extensive, well-replicated, and platform-independent. Understanding this evidence helps patients make decisions based on data rather than marketing.

The STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity or overweight to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, participants receiving semaglutide lost an average of 14.9 percent of their body weight compared to 2.4 percent in the placebo group. Additionally, 86.4 percent of semaglutide-treated participants achieved at least 5 percent weight loss, and 69.1 percent achieved at least 10 percent. This trial established semaglutide as one of the most effective pharmaceutical interventions for weight management, with efficacy far exceeding older weight loss medications and approaching results previously achievable only through bariatric surgery.

The SURMOUNT-1 trial, published by Jastreboff et al. in the New England Journal of Medicine in 2022, evaluated tirzepatide in 2,539 adults with obesity. The highest dose group (15 mg weekly) achieved an average weight reduction of 22.5 percent of body weight over 72 weeks — the largest average weight loss ever recorded in a pharmaceutical obesity trial. Even the lowest tirzepatide dose (5 mg) produced 15 percent average weight loss, comparable to the maximum semaglutide dose. Tirzepatide's dual mechanism as both a GIP and GLP-1 receptor agonist produces additive metabolic benefits that GLP-1 stimulation alone does not achieve.

These results apply equally whether the medication comes from Hims, Sequence, Trimi, or any other legitimate provider prescribing the same active ingredients at the same doses. The compounded versions of semaglutide and tirzepatide contain the identical active pharmaceutical ingredient as the brand-name products studied in these trials. What a quality provider adds is not better medication — the medication is the same — but better clinical guidance on dose titration, side effect management, and long-term treatment strategy. This is where Sequence's specialist model has genuine clinical value for complex cases, while Trimi's focused metabolic health providers deliver this expertise at a more accessible price point.

Where Hims Has the Edge

Where Sequence Has the Edge

Shared Limitations of Both Platforms

Why Trimi Compares Favorably to Both

For patients whose primary criteria are effective GLP-1 medication at the lowest sustainable price with quality clinical support, Trimi addresses the key cost and specialization gaps in both the Hims and Sequence models. At $99 per month for compounded semaglutide and $125 per month for compounded tirzepatide, Trimi's everyday pricing undercuts both competitors without requiring promotional codes, multi-month commitments, or limited-time offers.

The annual savings are substantial. A patient taking semaglutide for 12 months saves $600 to $1,200 compared to Hims and $1,800 to $3,600 compared to Sequence by choosing Trimi. For tirzepatide, the annual difference is even greater — up to $3,288 in savings compared to Sequence's highest tier. For patients considering switching from either platform, our guides on canceling Hims weight loss and canceling Sequence walk through the transition process step by step.

The Bottom Line

The Hims versus Sequence comparison represents the clearest budget-versus-premium trade-off in the GLP-1 telehealth market. Hims delivers an efficient, affordable GLP-1 prescription service backed by the stability of a publicly traded company. Sequence delivers a premium, clinically sophisticated weight management experience with obesity medicine specialists who bring genuine expertise to complex cases. Both are legitimate providers prescribing real medications through licensed clinicians.

However, the GLP-1 market has matured enough that patients no longer need to choose between cheap-and-generic or expensive-and-specialized. Trimi offers compounded semaglutide at $99 per month and compounded tirzepatide at $125 per month — with no consultation fees, no contracts, and providers who specialize in metabolic health. Over a 12-month treatment course, the cumulative savings compared to Sequence can exceed $3,600 while still receiving specialized clinical support that generalist platforms like Hims do not provide.

The medication produces the results, not the telehealth brand on the shipping label. Choose the provider that gives you the best combination of affordable pricing, clinical support, and treatment flexibility for the long term. We encourage patients to verify current pricing directly on each platform's website and compare total annual cost at your expected maintenance dose, not introductory prices at the lowest tier. For a broader view of the GLP-1 provider landscape, see our cheapest GLP-1 injections 2026 guide and our homepage to start your assessment.